Agendia’s genomic testing platforms help in matching each patient to the right treatment to help minimize under- and over-treatment, and improve their quality of life.
Agendia raises a $35,000,000 private equity from Athyrium Capital Management, LP.
Agendia raises a $4,839,000 grant from EASME.
Agendia raises a $18,145,710 venture round from Norgine Ventures.
September 23, 2009
Agendia raises a $23,000,000 series E round from Gilde Healthcare Partners and ING Group.
Agendia was founded by PROF. DR. RENÉ BERNARDS, PhD and PROF. LAURA VAN ‘T VEER, PhD.
August 28, 2007
Agendia raises a $34,000,000 series D round from Gilde Healthcare Partners.
Documentaries, videos and podcasts
June 7, 2021
New data on Agendia's MammaPrint test showed it could help identify patients at an ultra low risk of recurrence, including some who are likely to not see their tumor return for at least 20 years and could potentially skip chemotherapy--and the side effects that come with it.
November 20, 2020
Breast cancer diagnostic developer Agendia announced plans to integrate its genomic tests with Paige's artificial-intelligence-powered pathology services with the goal of building a new digital precision oncology platform.
May 8, 2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.